References
- Dahlhamer JM , LucasJ , ZelayaCet.al Prevalence of chronic pain and high-impact chronic pain among adults – United States, 2016. Morb. Mortal. Wkly. Rep.67(36), 1001–1006 (2018).
- Dowell D , HaegerichTM , ChouR. CDC guideline for prescribing opioids for chronic pain – United States, 2016. JAMA315(15), 1624–1645 (2016).
- Centers for Disease Control and Prevention . 2018 Annual Surveillance Drug-Related Risks and Outcomes – United States. Surveillance Special Report 91 (2018). www.cdc.gov/drugoverdose/pdf/pubs/2018-cdc-drug-surveillance-report.pdf
- Centers for Disease Control . Drug Overdose Deaths | Drug Overdose | CDC Injury Center. Centers for Disease Control and Prevention (2018). www.cdc.gov/drugoverdose/data/statedeaths.html
- Campbell G , BrunoR , LintzerisNet.al Defining problematic pharmaceutical opioid use among people prescribed opioids for chronic noncancer pain: do different measures identify the same patients? Pain 157(7), 1489–1498 (2016).
- Butler SF et.al Development and validation of the current opioid misuse measure. Pain130(1–2), 144–156 (2007).
- Butler SF , FernandezK , BenoitC , BudmanSH , JamisonRN. Validation of the revised screener and opioid assessment for patients with pain (SOAPP-R). J. Pain9(4), 360–372 (2008).
- Soelberg CD , BrownRE , DuVivier D , MeyerJE , RamachandranBK. The US opioid crisis: current federal and state legal issues. Anesth. Analg.125(5), 1675–1681 (2017).
- Moyo P , Simoni-WastilaL , GriffinBAet.al Impact of prescription drug monitoring programs (PDMPs) on opioid utilization among Medicare beneficiaries in 10 US States. Addiction112(10), 1784–1796 (2017).
- Mahajan G . Role of urine drug testing in the current opioid epidemic. Anesth. Analg.125(6), 2094–2104 (2017).
- Argoff CE , AlfordDP , FudinJet.al Rational urine drug monitoring in patients receiving opioids for chronic pain: consensus recommendations. Pain Med.19(1), 97–117 (2018).
- Manchikanti L , KayeAM , KnezevicNNet.al Responsible, safe, and effective prescription of opioids for chronic non-cancer pain: american society of interventional pain physicians (ASIPP) guidelines. Pain Physician20(2S), S3–S92 (2017).
- Eibl JK , GauthierG , PellegriniDet.al The effectiveness of telemedicine-delivered opioid agonist therapy in a supervised clinical setting. Drug Alcohol Depend.176, 133–138 (2017).
- Huskamp HA et.al How is telemedicine being used in opioid and other substance use disorder treatment? Health Aff. 37(12), 1940–1947 (2018).
- Rubin R . Using telemedicine to treat opioid use disorder in rural areas. JAMA322(11), 1029–1031 (2019).
- Yang YT , WeintraubE , HaffajeeRL. Telemedicine’s role in addressing the opioid epidemic. Mayo Clin. Proc.93(9), 1177–1180 (2018).
- Zheng W , NickaschM , LanderLet.al Treatment outcome comparison between telepsychiatry and face-to-face buprenorphine medication-assisted treatment for opioid use disorder. J. Addict. Med.11(2), 138–144 (2017).
- Weintraub E , GreenblattAD , ChangJ , HimelhochS , WelshC. Expanding access to buprenorphine treatment in rural areas with the use of telemedicine. Am. J. Addict.27(8), 612–617 (2018).
- Cohen SP , BaberZB , BuvanendranAet.al Pain management best practices from multispecialty organizations during the COVID-19 Pandemic and public health crises. Pain Med.21(7), 1331–1346 (2020).
- Shanthanna H , StrandNH , ProvenzanoDAet.al Caring for patients with pain during the COVID-19 pandemic: consensus recommendations from an international expert panel. Anaesthesia75(7), 935–944 (2020).
- US Department of Health and Human Services . Notification of Enforcement Discretion for Telehealth Remote Communications During the COVID-19 Nationwide Public Health Emergency. www.hhs.gov/hipaa/for-professionals/special-topics/emergency-preparedness/notification-enforcement-discretion-telehealth/index.html
- Webster LR , WebsterRM. Predicting aberrant behaviors in opioid-treated patients: preliminary validation of the opioid risk tool. Pain Med.6(6), 432–442 (2005).
- Lawrence R , MogfordD , ColvinL. Systematic review to determine which validated measurement tools can be used to assess risk of problematic analgesic use in patients with chronic pain. Br. J. Anaesth.119(6), 1092–1109 (2017).
- Kaye A D , JonesMR , KayeAMet.al Prescription opioid abuse in chronic pain: an updated review of opioid abuse predictors and strategies to curb opioid abuse: Part 1. Pain Physician20(2S), S93–S109 (2017).
- American Society of Addiction Medicine . Ensuring access to care in opioid treatment programs (2020). www.asam.org/Quality-Science/covid-19-coronavirus/access-to-care-in-opioid-treatment-program
- American Society of Addiction Medicine . Adjusting drug testing protocols (2020). www.asam.org/Quality-Science/covid-19-coronavirus/adjusting-drug-testing-protocols
- Litman RS , PagánOH , CiceroTJ. Abuse-deterrent opioid formulations. Anesthesiology128(5), 1015–1026 (2018).
- World Health Organization (WHO) . World health organization model list of essential medicines. (21st Edition) Geneva (2019).
- Substance Abuse and Mental Health Services Administration . Opioid Treatment Program (OTP) Guidance (2020). www.samhsa.gov
- Substance Abuse and Mental Health Services Administration . OTP guidance for patients quarantined at home with the coronavirus. (2020). https://www.samhsa.gov/sites/default/files/otp-covid-implementation-guidance.pdf
- Jones CM , CampopianoM , BaldwinG , McCance-KatzE. National and state treatment need and capacity for opioid agonist medication-assisted treatment. Am. J. Public Health105(8), e55–63 (2015).
- Fiscella K , WakemanSE , BeletskyL. Buprenorphine deregulation and mainstreaming treatment for opioid use disorder: X the X Waiver. JAMA Psychiatry76(3), 229–230 (2019).
- DEA . COVID-19 information page. www.deadiversion.usdoj.gov/coronavirus.html